We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

31 hedge funds and large institutions have $15.7M invested in Rein Therapeutics in 2017 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 9

63% more funds holding

Funds holding: 19 → 31 (+12)

1.69% less ownership

Funds ownership: 2.09% → 0.4% (-1.7%)

24% less capital invested

Capital invested by funds: $20.7M → $15.7M (-$5.03M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
31
Holders Change
+12
Holders Change %
+63.16%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
1
Reduced
4
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.96M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$594K
3
Northern Trust
Northern Trust
Illinois
+$239K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$218K
5
State Street
State Street
Massachusetts
+$215K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$8.25M
2
NC
Nexthera Capital
New York
-$1.27M
3
Millennium Management
Millennium Management
New York
-$1.07M
4
MIM
Monashee Investment Management
Massachusetts
-$836K
5
HCM
Highbridge Capital Management
New York
-$562K
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
26
Legal & General Group
United Kingdom
$12K +$11K +44 New
TCIM
27
TIAA CREF Investment Management
New York
$11K +$10.8K +43 New
Manulife (Manufacturers Life Insurance)
28
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$8K +$7.53K +30 New
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$6K +$5.52K +22 New
Wells Fargo
30
Wells Fargo
California
$4K +$4.01K +16 New
Barclays
31
Barclays
United Kingdom
$2K +$1.5K +6 New
NC
32
Nexthera Capital
New York
– -$1.27M -5,705 Closed
MIM
33
Monashee Investment Management
Massachusetts
– -$836K -3,750 Closed
HCM
34
Highbridge Capital Management
New York
– -$562K -2,522 Closed
Goldman Sachs
35
Goldman Sachs
New York
– -$418K -1,875 Closed
Neuberger Berman Group
36
Neuberger Berman Group
New York
– -$279K -1,250 Closed
Citadel Advisors
37
Citadel Advisors
Florida
– -$141K -634 Closed
Tudor Investment Corp
38
Tudor Investment Corp
Connecticut
– -$112K -500 Closed
ZP
39
Zimmer Partners
New York
– -$112K -500 Closed
PMFA
40
Plante Moran Financial Advisors
Michigan
– -$3K -15 Closed
1
2

RNTX Hedge Fund Activity: Q3 2017 in Review

31 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2017, worth a combined $15.7M — down 24% from $20.7M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new RNTX positions and 9 closed out — a net gain of 12 holders — while 1 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $2.96M. The largest seller was Bank of America, cutting an estimated $8.25M.

  • 31 institutional investors held Rein Therapeutics (RNTX) as of Q3 2017, up from 19 in Q2 2017.
  • Funds reported $15.7M of Rein Therapeutics stock for Q3 2017, down 24% quarter-over-quarter.
  • 21 funds opened new Rein Therapeutics positions in Q3 2017 and 9 closed out, a net change of +12 holders.
  • The largest Rein Therapeutics buyer in Q3 2017 was BlackRock, an estimated $2.96M added.
  • The largest Rein Therapeutics seller in Q3 2017 was Bank of America, an estimated $8.25M sold.

Based on aggregated 13F filings for Q3 2017.